Geron: 3 Key Takeaways for Long-Term Investors

On its third quarter of 2026 earnings call, held on Nov. 4, 2026, Geron (NASDAQ:GERN) announced that full-year net revenue will reach the mid- to high end of its guidance range of $220 million to $240 million. Growing commercial adoption of RYTELO (imetelstat), an enzyme-inhibiting drug approved for lower-risk myelodysplastic syndromes (MDS), a group of bone marrow disorders, provides expanding cash flow from community oncology practices. Three things management said stand out.

Community oncology clinics drive the majority of patient prescriptions, giving Geron a growing footprint in second-line blood disease treatment. Net product revenue reached $60.1 million in the third quarter, representing a 27% increase year over year.

An independent monitoring committee found the Phase III IMpactMF trial unlikely to hit its primary endpoint for overall survival, prompting management to stop the study. Ending the trial avoids future clinical trial spending and sharpens focus on existing commercial priorities.

Continue reading